Jardiance – Compliance Alert

Caution

This ad has patterns previously flagged by FDA.

Analysis of this 75s ad identified 4 enforcement patterns, primarily Visual Distraction. Patterns span Visual Distraction — “Outdoor & Physical Activity” identified at 16.8s, previously cited in BRUKINSA, COBENFY, Fasenra (x3). FDA enforcement letter on file dated Sep 9, 2025.

Recommended action: Flag for next MLR cycle: Visual content during safety information window (20s–69s) may distract from risk disclosure. Schedule creative revision to use static or neutral visuals during major statement.

Video Timeline

Risk disclosure: 19.7s – 68.5s (48.9s of 75.2s total — 65.0% of ad)

Risk Window

0s19s38s56s75s

Outdoor & Physical?Risk Window?

Patterns Detected (4)

Each pattern below is a known FDA enforcement concern, identified by matching this ad against 14 violation types from 34 FDA warning letters

Pattern	Dimension	Score	Evidence	CFR
Outdoor & Physical Activity Upbeat outdoor imagery shown while safety warnings are being read	Visual Distraction	38	7 clips	21 CFR 202.1(e)(1)	▶
FDA Concern: Risk information must be presented in a clear, conspicuous, and neutral manner without distracting visuals Previously cited: BRUKINSA, COBENFY, Fasenra (x3), Velsipity, Calquence
Family & Social Scenes Warm family scenes that emotionally minimize risk information	Visual Distraction	38	2 clips	21 CFR 202.1(e)(1)	▶
FDA Concern: Risk information must be presented in a clear, conspicuous, and neutral manner without distracting visuals Previously cited: Jardiance (x3), Contrave, Qulipta, Calquence, Austedo (x2)
Daily Activities Relatable lifestyle visuals that divert attention from safety disclosures	Visual Distraction	38	2 clips	21 CFR 202.1(e)(1)	▶
FDA Concern: Risk information must be presented in a clear, conspicuous, and neutral manner without distracting visuals Previously cited: Contrave, Velsipity, Qulipta, Fasenra (salsa)
Animated/Motion Graphics Motion graphics that visually compete with risk narration	Visual Distraction	38	3 clips	21 CFR 202.1(e)(1)	▶
FDA Concern: Risk information must be presented in a clear, conspicuous, and neutral manner without distracting visuals Previously cited: NEXLIZET (Lipid Lurkers)

Recommendations

high

Flag for next MLR cycle: Visual content during safety information window (20s–69s) may distract from risk disclosure. Schedule creative revision to use static or neutral visuals during major statement.

high

Escalate to regulatory affairs: FDA enforcement letter on file (Sep 9, 2025). Verify remediation status in PromoMats and confirm all content modifications address cited violations before next distribution.

Compliance Alert: Jardiance

Recommendations